Testosterone pellets (Testopel)


Indications for Prior Authorization:

  • Primary hypogonadism
    • Testicular failure due to bilateral torsion, orchitis, vanishing testes syndrome, cryptorchidism, or orchidectomy
  • Hypogonadotrophic hypogonadism
  • LHRH deficiency, pituitary hypothalamic injury from tumors, trauma, or radiation
  • Male delayed puberty

The following indications do not meet the criteria for use established by the Western Health Advantage Pharmacy and Therapeutics Committee:

  • Treatment of female patients with symptoms of menopause or decreased libido
  • Palliation therapy in post-menopausal women with breast cancer
  • Any other diagnosis not listed in the approved indications
  • The drug is not approvable for use in men with breast or prostate cancer

All of the following must be met:

  • Treatment failure with topical and intramuscular testosterone administration
  • Failure is defined as the inability to achieve normal plasma testosterone levels


  • Pellet SC implantation 150 mg to 450 mg every 3-6 months


2 months


Last review date: July 10, 2018